Navigation Links
Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report

SCOTTSDALE, Ariz., Feb. 26 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled MedPredict Thought Leader Insight & Analysis: Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel debates tough questions facing drug developers:

-- How should rheumatologists sequence/stack biologicals? What will

challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell?

-- How big of a benefit will oral dosing provide in this patient

population? Syk? Jak? p38? CCR? Will orals move RA treatment into

the community?

-- What do they hear from Pharma? What will Wyeth do when they return to

Amgen the rights to etanercept? How strong is AstraZeneca's

commitment to arthritis?

-- Why is it so hard to treat gout?

"There continue to be significant unmet needs in this market," says MedPredict President Jeffrey D. Berk. "According to our Panelists, only half of RA patients achieve remission on their first biological therapy and these remissions aren't durable. Even with completely new options many patients are left under-satisfied and demanding better results from their physicians. This report sheds light on these unmet needs and reveals Panelists' views of the most promising candidates."

Drugs/Companies mentioned in this report: allopurinol; febuxostat (Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Schering-Plough/Essex); Actemra (tocilizumab; Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc/anti-BR3 MAb Biogen/Genentech); LymphoStat-B(R) (belimumab; Human Genome Sciences/GSK); Atacicept (TACI-Ig; ZymoGenetics/Merck-Serono); BMS-582949 (BMS); 856553 (GSK); CP-690550 (Pfizer); INCB18424 (Incyte); tamatinib (R788; Rigel); baminercept (BG9924; Biogen); MLN-3897 (Millennium/Sanofi-Aventis); AZD5672 (AstraZeneca); RWJ-445380 (Alza/J&J); AZD9056 (AstraZeneca); everolimus (RAD-001; Novartis); MM-093 (Merrimack)

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize
2. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
3. CardioDynamics Provides 2007 Shareholder Meeting Update
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
6. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
7. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
8. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. NxStage Medical Provides Update on Medisystems Acquisition
11. VaxGen Files 2006 Financial Statements and Provides Cash Update
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):